Next Article in Journal
Experimental Evidence Shows Salubrinal, an eIF2α Dephosphorylation Inhibitor, Reduces Xenotoxicant-Induced Cellular Damage
Previous Article in Journal
Deep Sequencing Analysis of miRNA Expression in Breast Muscle of Fast-Growing and Slow-Growing Broilers
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2015, 16(7), 16263-16274;

RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo

1,2,†,* , 1,2,†
Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Department of Anesthesiology, the First Affiliated Hospital of Bengbu Medical College, Anhui 233004, China
Department of Anatomy, Histology and Embryology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
Department of Orthopedic Sports Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
These authors contributed equally to this work.
Authors to whom correspondence should be addressed.
Academic Editor: Antonella Piozzi
Received: 12 May 2015 / Revised: 29 June 2015 / Accepted: 30 June 2015 / Published: 17 July 2015
(This article belongs to the Section Materials Science)
Full-Text   |   PDF [1672 KB, uploaded 17 July 2015]   |  


Gastric cancer, a high-risk malignancy, is a genetic disease developing from a cooperation of multiple gene mutations and a multistep process. Gene therapy is a novel treatment method for treating gastric cancer. Here, we developed a novel Arg-Gly-Asp (RGD) peptides conjugated copolymers nanoparticles-based gene delivery system in order to actively targeting inhibit the growth of gastric cancer cells. These transcription factor (AP-2α) expression plasmids were also encapsulated into pluronic triblock copolymers nanoparticles which was constituted of poly(ethylene glycol)-block-poly(propylene glycol)- block-poly(ethylene glycol) (PEO-block-PPO-block-PEO, P123). The size, morphology and composition of prepared nanocomposites were further characterized by nuclear magnetic resonance (NMR), transmission electron microscopy (TEM) and dynamic light scattering (DLS). In MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) analysis, these nanocomposites have minor effects on the proliferation of GES-1 cells but significantly decreased the viability of MGC-803, suggesting they own low cytotoxicity but good antitumor activity. The following in vivo evaluation experiments confirmed that these nanocomposites could prevent the growth of gastric cancer cells in the tumor xenograft mice model. In conclusion, these unique RGD peptides conjugated P123 encapsulated AP-2α nanocomposites could selectively and continually kill gastric cancer cells by over-expression of AP-2α in vitro and in vivo; this exhibits huge promising applications in clinical gastric cancer therapy. View Full-Text
Keywords: gastric cancer; gene therapy; triblock copolymers; AP-2α; RGD gastric cancer; gene therapy; triblock copolymers; AP-2α; RGD

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Wang, W.; Liu, Z.; Sun, P.; Fang, C.; Fang, H.; Wang, Y.; Ji, J.; Chen, J. RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo. Int. J. Mol. Sci. 2015, 16, 16263-16274.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top